Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia

Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber, Henriette, Edenhofer, Simone, Estenfelder, Sven, Stilgenbauer, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308588/
https://www.ncbi.nlm.nih.gov/pubmed/28223822
http://dx.doi.org/10.2147/OTT.S102646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308588/
https://www.ncbi.nlm.nih.gov/pubmed/28223822
http://dx.doi.org/10.2147/OTT.S102646

Ejemplares similares